| Overview |
| bs-3949R-Cy5 |
| LYK5 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LYK5 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 92335 |
| Cytoplasm, Nucleus |
| Serologically defined breast cancer antigen NY BR 96; STRAD alpha; Protein kinase LYK5; STE20 related adapter protein; STRAD; STRAA_HUMAN. |
| Members of the STE-20 like kinase family are known to stimulate MAPK pathways by directly activating MAPKKK. LYK5 is a novel pseudokinase member of this family consisting of a STE-20 like kinase domain but lacks several residues that are required for its catalytic activity. It specifically binds LKB1 and plays a key role in regulating the tumor suppressor activities of LKB1. It functions as an upstream activator of LKB1 and also directs the sub-cellular localization of LKB1 by anchoring it in the cytoplasm. LYK5-LKB1 interaction results in phosphorylation of LYK5 and enhanced autophosphorylation of LKB1. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz